AP2488A - Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder - Google Patents

Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder

Info

Publication number
AP2488A
AP2488A AP2007003953A AP2007003953A AP2488A AP 2488 A AP2488 A AP 2488A AP 2007003953 A AP2007003953 A AP 2007003953A AP 2007003953 A AP2007003953 A AP 2007003953A AP 2488 A AP2488 A AP 2488A
Authority
AP
ARIPO
Prior art keywords
agomelatine
treatment
anxiety disorder
generalized anxiety
medicaments intended
Prior art date
Application number
AP2007003953A
Other languages
English (en)
Other versions
AP2007003953A0 (en
Inventor
Delalleau Bruno
Mark Millan
Elisabeth Mocaer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2488(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AP2007003953A0 publication Critical patent/AP2007003953A0/xx
Application granted granted Critical
Publication of AP2488A publication Critical patent/AP2488A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2007003953A 2006-04-07 2007-03-26 Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder AP2488A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0603083A FR2899472B1 (fr) 2006-04-07 2006-04-07 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee

Publications (2)

Publication Number Publication Date
AP2007003953A0 AP2007003953A0 (en) 2007-04-30
AP2488A true AP2488A (en) 2012-10-03

Family

ID=37308935

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007003953A AP2488A (en) 2006-04-07 2007-03-26 Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder

Country Status (44)

Country Link
US (1) US7960438B2 (ar)
EP (1) EP1842535B1 (ar)
JP (1) JP4880031B2 (ar)
KR (1) KR20070100657A (ar)
CN (1) CN101049290B (ar)
AP (1) AP2488A (ar)
AR (1) AR060349A1 (ar)
AT (1) ATE477798T1 (ar)
AU (1) AU2007201527B2 (ar)
BR (1) BRPI0701601A (ar)
CA (1) CA2584060C (ar)
CO (1) CO5840252A1 (ar)
CR (1) CR9019A (ar)
CY (1) CY1111287T1 (ar)
DE (1) DE602007008494D1 (ar)
DK (1) DK1842535T3 (ar)
EA (1) EA012608B1 (ar)
ES (1) ES2351062T3 (ar)
FR (1) FR2899472B1 (ar)
GE (1) GEP20094743B (ar)
GT (1) GT200700032A (ar)
HK (1) HK1108367A1 (ar)
HR (1) HRP20100577T1 (ar)
IL (1) IL182407A (ar)
JO (1) JO3440B1 (ar)
MA (1) MA28987B1 (ar)
ME (1) ME01865B (ar)
MX (1) MX2007004100A (ar)
MY (1) MY143269A (ar)
NI (1) NI200700084A (ar)
NO (1) NO20071774L (ar)
NZ (1) NZ554347A (ar)
PE (1) PE20080174A1 (ar)
PL (1) PL1842535T3 (ar)
PT (1) PT1842535E (ar)
RS (1) RS51485B (ar)
SA (1) SA07280161B1 (ar)
SG (1) SG136881A1 (ar)
SI (1) SI1842535T1 (ar)
TN (1) TNSN07118A1 (ar)
TW (1) TWI374736B (ar)
UY (1) UY30262A1 (ar)
WO (1) WO2007116136A1 (ar)
ZA (1) ZA200702865B (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
IT201900002913A1 (it) 2019-03-01 2020-09-01 Nicola Pescosolido Composto utile per il trattamento del glaucoma
CN110867197A (zh) * 2019-10-23 2020-03-06 吴杰 语音交互过程中实时打断语音机器人的方法及设备

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447285A1 (fr) * 1990-02-27 1991-09-18 Adir Et Compagnie Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG45100A1 (en) * 1994-03-07 1998-01-16 Ibm Improvements in image processing
DE19532842C1 (de) * 1995-09-05 1996-12-19 Ibm Bildaufnahmesystem
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0447285A1 (fr) * 1990-02-27 1991-09-18 Adir Et Compagnie Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.09.03 THE BENEFITS OF AGOMELATINE BEYOND ANTIDEPRESSANT *
Chilman-Blair K. et al *
MARIUSZ PAPP et al. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behavioural pharmacology, 2006, fevral', ���17, s. 9-18 c.9, 10, 14, 17 � *
P.2.102 EFFECT OF AGOMELATINE ON THE SLEEP EEG IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MMD) *

Also Published As

Publication number Publication date
ATE477798T1 (de) 2010-09-15
ME01865B (me) 2011-04-30
CA2584060C (fr) 2011-04-26
EP1842535A1 (fr) 2007-10-10
SI1842535T1 (sl) 2010-10-29
CO5840252A1 (es) 2007-12-31
HRP20100577T1 (hr) 2010-11-30
AR060349A1 (es) 2008-06-11
AP2007003953A0 (en) 2007-04-30
MX2007004100A (es) 2009-02-16
TWI374736B (en) 2012-10-21
CY1111287T1 (el) 2015-08-05
HK1108367A1 (en) 2008-05-09
PL1842535T3 (pl) 2011-01-31
FR2899472A1 (fr) 2007-10-12
KR20070100657A (ko) 2007-10-11
CR9019A (es) 2008-10-28
BRPI0701601A (pt) 2007-12-11
EA200700574A3 (ru) 2007-12-28
MA28987B1 (fr) 2007-11-01
AU2007201527A1 (en) 2007-10-25
SG136881A1 (en) 2007-11-29
PE20080174A1 (es) 2008-03-29
ZA200702865B (en) 2008-07-30
CA2584060A1 (fr) 2007-10-07
CN101049290A (zh) 2007-10-10
DK1842535T3 (da) 2010-11-15
ES2351062T3 (es) 2011-01-31
TNSN07118A1 (fr) 2008-06-02
WO2007116136A1 (fr) 2007-10-18
JP4880031B2 (ja) 2012-02-22
SA07280161B1 (ar) 2010-10-23
FR2899472B1 (fr) 2008-09-12
NO20071774L (no) 2007-10-08
PT1842535E (pt) 2010-09-28
MY143269A (en) 2011-04-15
IL182407A0 (en) 2008-01-20
AU2007201527B2 (en) 2012-08-09
US20070238792A1 (en) 2007-10-11
EA200700574A2 (ru) 2007-10-26
JO3440B1 (ar) 2019-10-20
GEP20094743B (en) 2009-07-27
UY30262A1 (es) 2007-05-31
NI200700084A (es) 2008-04-24
IL182407A (en) 2016-02-29
TW200808295A (en) 2008-02-16
CN101049290B (zh) 2012-10-31
DE602007008494D1 (de) 2010-09-30
EA012608B1 (ru) 2009-10-30
EP1842535B1 (fr) 2010-08-18
NZ554347A (en) 2008-08-29
JP2009532446A (ja) 2009-09-10
US7960438B2 (en) 2011-06-14
GT200700032A (es) 2007-10-31
RS51485B (en) 2011-04-30

Similar Documents

Publication Publication Date Title
AP2488A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
GB2439393B (en) Cannabinoids for use in the treatment of neuropathic pain
EP1971278A4 (en) PROCESS FOR SURFACE TREATMENT OF THE SKIN
HK1170429A1 (en) Alpha aminoamide derivatives useful in the treatment of cognitive disorders
IL202515A (en) Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases
SI1978947T1 (sl) Nitrooksiderivati za uporabo pri zdravljenju mišičnih distrofij
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
SI2137141T1 (sl) Arilamidi bifenil-4-il-sulfonske kisline in njihova uporaba kot terapevtska sredstva
EP2205236A4 (en) NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS
AP2008004379A0 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient
HK1203160A1 (en) Tapentadol for the treatment of pain in arthrosis (tapentadol)
IL212672A (en) Cycloandesdepsipeptide compounds and their use in drug production
GB0724238D0 (en) Apparatus for use in the care of animals
HK1139855A1 (en) Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
ZA201001207B (en) Therapeutic formulations for the treatment of cold and flu-like symptoms
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
EP2099444A4 (en) USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
AP2656A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
SG136882A1 (en) Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders